Konakion

Phytomenadione, the active ingredient in Konakion, is a vitamin K (phytomenadione) presented as an injectable formulation for intramuscular, intravenous and oral use. It is employed to prevent and treat vitamin K deficiency, to protect newborns from hemorrhagic disease, and to reverse the anticoagulant effects of agents such as warfarin.

GNH USA supplies Konakion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Konakion (phytomenadione) acts as a vitamin K replacement to support the coagulation cascade.

- Vitamin K deficiency: restores normal clotting factor activity in patients with deficient levels. - Hemorrhagic disease of the newborn: provides prophylaxis to newborns at risk of bleeding. - Anticoagulant therapy reversal: rapidly reverses the effects of warfarin or other vitamin K antagonists.

Adverse reactions to Konakion are generally infrequent but may occur following parenteral or oral administration.

Common Side Effects: - Injection site pain: mild discomfort at the site of intramuscular or intravenous administration. - Nausea: transient feeling of queasiness after oral dosing. - Headache: mild headache reported in some patients. - Fever: low‑grade temperature elevation occasionally observed.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hemolysis: rare destruction of red blood cells leading to anemia. - Hypercoagulability: uncommon excessive clot formation, especially in patients with underlying thrombophilia.

When using Konakion, clinicians should observe several safety considerations to minimize risk.

- Assess vitamin K status: evaluate baseline coagulation parameters before administration. - Monitor anticoagulated patients: check INR or PT values after reversal therapy. - Use caution in newborns: ensure appropriate dosing and observe for signs of bleeding. - Avoid in patients with known hypersensitivity: discontinue if allergic reaction occurs. - Pregnancy and lactation: use only if benefit outweighs potential risk, as data are limited. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Konakion may interact with other medicines that affect coagulation or vitamin K metabolism.

Major Interactions (Avoid): - Warfarin: concurrent use can blunt anticoagulant effect, requiring dose adjustment. - Broad‑spectrum antibiotics (e.g., cephalosporins): may reduce gut flora‑derived vitamin K, altering response. - High‑dose vitamin K supplements: can diminish the intended reversal effect.

Moderate Interactions (Monitor Closely): - Heparin: combined effect on clotting may increase bleeding risk. - Oral contraceptives: potential alteration of coagulation balance. - Lipid‑lowering agents (e.g., statins): may affect vitamin K‑dependent pathways.